Caloric vestibular stimulation for the management of motor and non-motor symptoms in Parkinson's disease by Wilkinson, David et al.
Kent Academic Repository
Full text document (pdf)
Copyright & reuse
Content in the Kent Academic Repository is made available for research purposes. Unless otherwise stated all
content is protected by copyright and in the absence of an open licence (eg Creative Commons), permissions 
for further reuse of content should be sought from the publisher, author or other copyright holder. 
Versions of research
The version in the Kent Academic Repository may differ from the final published version. 
Users are advised to check http://kar.kent.ac.uk for the status of the paper. Users should always cite the 
published version of record.
Enquiries
For any further enquiries regarding the licence status of this document, please contact: 
researchsupport@kent.ac.uk
If you believe this document infringes copyright then please contact the KAR admin team with the take-down 
information provided at http://kar.kent.ac.uk/contact.html
Citation for published version
Wilkinson, David T. and Podlewska, Aleksandra and Banducci, Sarah and Pellatt-Higgins, Tracy
and Slade, Martin and Bodani, Mayur and Sakel, Mohamed and Smith, Lanty and LeWitt, Peter
and Ade, Kristen  (2019) Caloric vestibular stimulation for the management of motor and non-motor
symptoms in Parkinson's disease.   Parkinsonism and Related Disorders .       (In press)
DOI
doi.org/10.1016/j.parkreldis.2019.05.031




Contents lists available at ScienceDirect
Parkinsonism and Related Disorders
journal homepage: www.elsevier.com/locate/parkreldis
Short communication
Caloric vestibular stimulation for the management of motor and non-motor
symptoms in Parkinson's disease
David Wilkinsona,∗, Aleksandra Podlewskaa, Sarah E. Banduccib, Tracy Pellat-Higginsc,
Martin Sladed, Mayur Bodanie, Mohamed Sakelf, Lanty Smithb, Peter LeWittg, Kristen K. Adeb
a School of Psychology, University of Kent, Canterbury, UK
b Scion NeuroStim, LLC, Durham, NC, USA
c Centre for Health Services Studies, University of Kent, Canterbury, UK
d Yale University, School of Public Health, New Haven, CT, 06510, USA
eNeuropsychiatry Service, Kent & Medway NHS and Social Care Partnership Trust, UK
f East Kent Neuro-Rehabilitation Service, East Kent Hospitals University NHS Foundation Trust, Canterbury, UK
g Parkinson's Disease & Movement Disorders Program, Henry Ford Hospital and Wayne State University School of Medicine, West Bloomfield, MI, 48322, USA








A B S T R A C T
Introduction: A recent case study showed that repeated sessions of caloric vestibular stimulation (CVS) relieved
motor and non-motor symptoms associated with Parkinson's disease (PD). Here we sought to confirm these
results in a prospective, double-blind, randomized, placebo treatment-controlled study.
Methods: 33 PD subjects receiving stable anti-Parkinsonian therapy completed an active (n=16) or placebo
(n=17) treatment period. Subjects self-administered CVS at home twice-daily via a portable, pre-programmed,
solid-state ThermoNeuroModulation (TNM™) device, which delivered continually-varying thermal waveforms
through aluminum ear-probes mounted on a wearable headset. Subjects were followed over a 4-week baseline
period, 8 weeks of treatment and then at 5- and 24-weeks post-treatment. At each study visit, standardized
clinical assessments were conducted during ON-medication states to evaluate changes in motor and non-motor
symptoms, activities of daily living, and quality of life ratings.
Results: Change scores between baseline and the end of treatment showed that active-arm subjects demonstrated
clinically-relevant reductions in motor and non-motor symptoms that were significantly greater than placebo-
arm subjects. Active treatment was also associated with improved scores on activities of daily living assessments.
Therapeutic gains were still evident 5 weeks after the end of active treatment but had started to recede at 24
weeks follow-up. No serious adverse events were associated with device use, and there was high participant
satisfaction and tolerability of treatment.
Conclusion: The results provide evidence that repeated CVS can provide safe and enduring adjuvant relief for
motor and non-motor symptoms associated with PD.
1. Introduction
In a single-case study, daily sessions of caloric vestibular stimulation
(CVS) were associated with a ∼50% reduction in both motor and non-
motor symptoms of Parkinson's disease (PD) which were still evident 5
months after treatment cessation [1]. CVS was self-administered at
home via a portable, solid-state, device that discharged time-varying
thermal waveforms via ear pieces housed in a headset [2]. This result
builds on evidence from laboratory experiments showing that vestib-
ular stimulation in PD can increase functional neural connectivity and
improve certain aspects of motor control [3–9]. Together, these data
prompted the current double-blinded, placebo-controlled study which
sought to determine whether CVS might provide lasting, clinically-re-
levant improvement of both motor and non-motor features of PD.
2. Methods
PD patients were referred from clinical neuroscience services in
West and East Kent (U.K.) or were recruited through local branches of
the charity Parkinson's UK. Individuals were eligible for study inclusion
if they met the diagnostic UK Parkinson's Disease Society Brain Bank
Criteria for PD and experienced limitations to their activities of daily
https://doi.org/10.1016/j.parkreldis.2019.05.031
Received 18 October 2018; Received in revised form 20 May 2019; Accepted 21 May 2019
∗ Corresponding author. School of Psychology, University of Kent, Canterbury, Kent, CT2 7NP, UK.
E-mail address: dtw@kent.ac.uk (D. Wilkinson).
Parkinsonism and Related Disorders xxx (xxxx) xxx–xxx
1353-8020/ © 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/BY-NC-ND/4.0/).
Please cite this article as: David Wilkinson, et al., Parkinsonism and Related Disorders, https://doi.org/10.1016/j.parkreldis.2019.05.031
living. Patients were receiving stable regimens of anti-Parkinsonian
medications. Patients with prior exposure to neurostimulation and/or
known inner ear pathology were excluded from the study.
2.1. Study design
Eligible subjects completed a 4-week baseline evaluation com-
prising assessments repeated in the first and fourth week. They were
randomized (1:1 ratio) to active or placebo treatment groups. CVS
treatments were self-administered at home for 8 weeks. Behavioral
assessments were repeated midway through the 8-week treatment
period, at the end of treatment, and then 5 weeks later. Subjects who
remained contactable and consented to remain blinded to treatment
allocation were also evaluated at approximately 6 months after treat-
ment. All evaluations were conducted at the homes of subjects by the
same blinded clinical researcher. Assessments were performed when
subjects were in the ON medication state (timed to occur at the same
time relative to the last dose of anti-Parkinsonian medication). The
outcome measures can be found in Table 1.
Approval was obtained from the East Midlands NHS research ethics
committee. Written informed consent was obtained from all subjects at
study enrollment. The study was pre-registered at ClinicalTrials.gov as
NCT02703844.
2.2. Stimulation protocol
CVS was administered using the TNM™ Device (Supplemental
Fig. 1) recently cleared for market entry in both the United States (by
the FDA via DEN170023) and the European Union (by BSI via EC
Certificate CE 651494) for the prophylactic treatment of episodic mi-
graine in adolescents and adults 12 years and older (U.S.) and adults
(E.U.) [10]. The TNM™ Device is an Investigational Device that is
limited by United States and European Law to Investigational Use. It
can only be used by PD patients in the setting of a clinical trial and is
not available for sale. CVS treatment involved lying on a 22°-elevated
wedge pillow to orient the horizontal semi-circular canal vertically
(thereby maximizing vestibular activation). Active treatment involved
the simultaneous delivery of a time-varying, warm, saw-tooth thermal
(37 °C–42 °C) stimulus to one ear and a cold saw-tooth thermal
(37 °C–17 °C) stimulus to the other ear for approximately 19-min
(Supplemental Fig. 2). Subjects were instructed to separate their twice-
daily treatments by at least 1 h. Every 2 days the warm and cold wa-
veforms were switched from one ear to the other to avoid the possible
induction of a lasting, lateral, vestibular asymmetry [11]. By slow
warming and cooling of inner ear structures, it was possible to avoid
vertigo and nausea that can result from chilled water irrigation. In the
placebo treatment condition, subjects underwent the same 19-min
treatment choreography twice daily; however, no power was delivered
to the heating and cooling elements. To maintain treatment blinding,
treatment was discussed as brainstem modulation and no reference to
the thermal stimulus was made. Subjects were told that they might or
might not feel temperature changes in their ears and that this would not
be an indicator of active or placebo treatment; rather, temperature
changes are naturally felt by some people and not by others. Subjects
were told that they had a 50% likelihood of receiving either placebo or
active treatment. Those allocated to the placebo treatment arm were
promised the later opportunity to receive active treatment if the study
showed positive outcomes.
2.3. Statistical analyses
Efficacy analysis was conducted on the per protocol (PP) dataset at
the end of active treatment and at 5-week and 24-week follow-ups. It
included only those subjects who completed the study without a major
protocol violation. Subjects who withdrew or changed dose or type of
medications used to treat symptoms associated with PD prior to the end
Table 1





Age (y) 68.0 (12.0) 71.3 (7.0) 0.337
Male sex, No. (%) 10 (62.5%) 14 (82.4%) 0.201
Years of education+ 15 (12, 21) 14 (12, 22) 0.863
Years since PD diagnosis+ 10 (2, 28) 5 (2,14) 0.009
Years on dopamine replacement
therapy+
10 (1, 28) 5 (2, 14) 0.025
VAS score+ 7 (1, 10) 7 (1, 10) 0.630





Concomitant therapy at baseline, n (%)
Oral levodopa-based therapy 15 (93.8%) 17 (100%) 0.295
Dopamine agonist 11 (68.8%) 7 (41.1%) 0.166
MAO-B inhibitor 3 (18.8%) 5 (29.4%) 0.688
COMT inhibitor 6 (37.5%) 3 (17.6%) 0.438
Amantadine 2 (12.5%) 2 (11.8%) 1.000
Anticholinergic 1 (6.3%) 1 (5.8%) 1.000
Antidepressant/ Anti-anxiety 6 (37.5%) 6 (35.3%) 1.000
Duodopa 1 (6.3%) 0 (0.0%) 1.000
Incontinence 4 (25.0%) 3 (5.9%) 1.000
Sleep Aid 1 (6.3%) 2 (11.8%) 1.000
Pain/cramping 3 (18.8%) 5 (29.4%) 0.688
Laxative 0 (0.0%) 1 (5.9%) 1.000
Central acteylcholinesterase inhibitor 1 (6.3%) 2 (11.8%) 1.000
Blood Pressure 6 (37.5%) 4 (23.5%) 0.465
Deep Brain Stimulation 0 (0.0%) 0 (0.0%) 1.000
Baseline assessment scores (average± SD)
MDS-UPDRS
Part I 17.3 (5.8) 15.8 (4.9) 0.441
Part II 23.0 (9.3) 21.7 (6.1) 0.644
Part III 48.8 (16.7) 42.3 (16.0) 0.262
Hoehn Yahr+ 3.0 (2.0, 4.0) 2.0 (2.0, 4.0) 0.128
PIGD 8.5 (4.3) 7.1 (4.5) 0.344
NMSS total score 129.0 (31.7) 125.0 (31.5) 0.714
Domain 1: Cardiovascular/falls+ 0 (0.0, 12.0) 0.5 (0.0,
10.5)
0.666
Domain 2: Sleep/fatigue 21.8 (6.2) 19.9 (9.3) 0.476
Domain 3: Mood/cognition 23.8 (12.5) 25.7 (16.6) 0.714
Domain 4: Perceptual
/hallucinations+
0 (0, 16) 0 (0, 15) 0.425
Domain 5: Attention/memory 14.8 (11.6) 15.4 (9.1) 0.869
Domain 6: Gastrointestinal tract 13.1 (8.5) 11.9 (6.6) 0.658
Domain 7: Urinary 20.7 (8.4) 17.3 (9.0) 0.273





















Epworth Sleepiness Scale 14.7 (5.4) 10.4 (6.2) 0.044











10 meter walk fast-paced 5.3 (1.1) 4.7 (1.3) 0.154
2 minute walk 71.0 (24.9) 80.6 (32.3) 0.349
PDQ-39 33.7 (10.4) 30.3 (8.8) 0.318





EQ-5D-5L 0.63 (0.14) 0.66 (0.08) 0.451
SF-12 PCS 32.0 (5.9) 35.9 (5.7) 0.061
SF-12 MCS 48.53 (10.6) 46.5 (8.6) 0.557
Note: + indicates non-normal distribution of data. In these cases, values are
reported as median± range low value, high value. Differences between groups
were evaluated using Student's t test (in the case of normal distributions),
Mann-Whitney U tests (in the case of non-normal distributions) or Fisher's exact
test to compare proportions. VAS provided a patient-reported measure for
perceived efficacy of levodopa-based therapies for addressing PD symptoms.
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of the treatment period were excluded from the PP analysis. The in-
tention-to-treat analysis is reported elsewhere [12].
Outcomes were investigated using analysis of covariance to com-
pare the change in the mean response (from the average of week 1 and
4 baseline scores) across treatment groups using an alpha of 0.05. The
outcomes were adjusted for baseline symptom severity by including the
baseline measure as a covariate. Outcomes with non-normal distribu-
tions were analyzed using Wilcoxon Rank Sum tests to compare the
median change in response across treatment groups. The Hodges-
Lehmann method was used to calculate median difference and con-
fidence intervals. Analysis was performed using SAS 9.4 (SAS Institute,
Cary, NC, USA).
2.4. Missing data
Less than 5% of data were missing at week 12 in the PP dataset for
all outcomes, with the exception of the 10-m fast-paced walk (12%
missing), 2-min walk (6% missing) and the Timed-Up-and-Go (6%
missing).
3. Results
Forty-six subjects on stable anti-Parkinsonian medication were
randomized and received at least one CVS treatment. Of these, 33
subjects completed the full treatment period with no major protocol
violations and were included in the PP analysis. Thirty-one and 27
subjects, respectively, completed the 5-week and 6-month follow-up
assessments. The attrition rate was similar for the active and placebo
treatments. The demographics and assessment scores at baseline and
concomitant medications were similar between the active and placebo
groups (Table 1, Supplemental Table 1). The clinical assessment results
for the PP group are summarized in Table 2 and illustrated in
Supplemental Fig. 3. Individual outcome data can be found in the fol-
lowing online repository: https://data.mendeley.com/datasets/
m7ths6gdv9/1.
3.1. Non-motor symptom (NMS) outcomes
Evaluation of the change in MDS-UPDRS Part I (Non-Motor Aspects
of Experiences of Daily Living) from baseline to the end of the treatment
period revealed that the active group experienced a significantly
greater reduction in the overall burden of NMS relative to the placebo
treatment group. Therapeutic gains for this assessment were greatest 5
weeks after the cessation of treatment although change scores at both
time-points surpassed a previously established minimal clinically im-
portant difference (MCID) [13]. Likewise, active CVS treatment subjects
demonstrated significantly greater reductions in NMSS total score than
the placebo arm subjects at the end of treatment and which again
showed the largest therapeutic gains at the 5-week follow-up assess-
ment. Substantive improvements were demonstrated in most NMSS
sub-domains. At the individual subject level, 14 of the 16 active PP
subjects demonstrated reductions ≥10 points on one or more domains
of the NMSS (Supplemental Fig. 4). Supplemental exploratory post-hoc
analysis indicated that there were no interactions with sex, age, time
since PD diagnosis, time on anti-Parkinsonian medication, or the VAS
score and the observed treatment responses for the NMSS total score.
Active arm subjects also demonstrated statistically significant im-
provements in MoCA scores that persisted through the 5-week follow-
up.
3.2. Motor symptoms, ADLs and complications
Active arm subjects demonstrated durable improvements in the
MDS-UPDRS Part II (motor aspects of experiences of daily living) and
Part III (motor exam) scores that were significantly greater than those
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MCIDs [13,14]. Therapeutic responses were not influenced by sex, age,
time since diagnosis, time on anti-Parkinsonian medication, or VAS.
Statistically significant differences were also observed in the Modified
Schwab & England ADL scale, the 10-m self-paced walk and the Timed-
Up-and-Go. Active treatment was also associated with reductions in the
MDS-UPDRS Part IV (motor complications) driven primarily by reduced
dyskinesias (Supplemental Table 2).
3.3. Quality of life
Active treatment subjects demonstrated improvements in PDQ-39
scores relative to baseline at weeks 12 and 17 that exceeded the MCID
[15]. However, the therapeutic gains remained as non-significant
trends.
3.4. Blinding
At the 5-week follow-up, subjects were asked to guess their treat-
ment allocation. No active subjects guessed that they had received ac-
tive treatment: 9 guessed placebo treatment and 6 said that they were
unsure of their allocation (1 response was missing). 1 placebo treatment
subject guessed receiving active treatment, 12 guessed placebo treat-
ment and 4 were unsure.
3.5. Safety
Thirty four adverse events were reported in the 46 randomized
subjects: 24 in the active group and 10 in the placebo group. The likely
cause of all adverse events was determined by independent clinical
adjudication. Three adverse events were classified as “serious”, but
none was deemed to be related to device use. Four adverse events (i.e.,
ear discomfort, dizziness/motion sickness and migraine) were con-
sidered to be “possibly” related to device use; however, none was
considered to be severe, and all resolved after the cessation of device
use. All other adverse events were minor and were most likely attri-
butable to PD rather than to study involvement. For full details, see Ref.
[12].
3.6. Device usability and satisfaction
All 33 PP subjects completed a device-usability survey at the end of
the treatment period. Twenty-five subjects found the device ‘easy to use
at home’, 2 had no opinion and 6 subjects said that the device was not
easy to use but continued anyway. Nearly all subjects found the actual
time spent treating as ‘enjoyable’ or ‘acceptable’, with 1 expressing no
preference and 2 describing it as ‘challenging to maintain’. When asked
to rate their overall experience with the device, 5 active and 5 placebo
treatment subjects described it as ‘very positive’, 7 active and 11 pla-
cebo treatment subjects described it as ‘somewhat positive’, 2 active
subjects described it as ‘somewhat negative’ and 2 active and 1 placebo
treatment expressed no preference.
4. Discussion
The results from this randomized, double-blind, placebo-controlled
study in PD patients demonstrate that twice daily active treatment for 8
weeks with the CVS device was associated with clinically-relevant im-
provements in both motor and non-motor features of PD. These im-
provements were detected at the end of active treatment and, in the
majority of instances, therapeutic gains were greater 5 weeks after
treatment cessation. At 6 months follow-up, most of the gains had re-
turned to baseline status although there was some evidence of residual
effect. These clinical improvements were obtained without significant
safety concerns; no serious adverse events likely to be device-related
were reported, and subjects described their experience with the device
as largely positive.
Given the robust clinical effects, the failure of active-treatment
subjects to accurately guess their treatment allocation was surprising.
This lack of awareness may partly be explained by a difficulty per-
ceiving the gradual symptom reduction which occurred over days to
weeks in comparison with the visible motor improvements that occur
more abruptly with anti-Parkinsonian medications. Additionally, some
patients with PD do not strongly associate their NMS with Parkinsonism
[16] which, in the current study, may have made some subjects less
likely to attribute their NMS improvement to device treatment.
The successful concealment of allocation in this study provides good
reason to suggest that the clinical improvements were driven by more
than just a placebo response. Rather, the highly similar trajectory of
response curves in the active group from week 0 to week 36 across
several independent measures of both motor and non-motor function
support the likelihood that efficacy is driven by a genuine physiological
mechanism of action which, given the durability of effect, may involve
long-term plastic change [17,18]. CVS is known to activate a variety of
ascending cortical and subcortical pathways implicated in PD sympto-
mology [19,20]. Its means of induction sets it apart from all known
pharmacological and other neuro-modulatory procedures which are
non-endogenous in nature and chemically/anatomically localized.
Coupled with the diffuse clinical effects reported here, these char-
acteristics speak to domain-general mechanisms of action such as those
associated with cortical entrainment and neurovascular coupling which
help to synchronize neural activity. In line with this, we recently
showed that the CVS waveform applied in this study induced oscilla-
tions in cerebrovascular dynamics suggestive of pontine entrainment
[2]. Future studies will seek to further elucidate these mechanisms in
parallel with larger-scale clinical evaluation.
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